Literature DB >> 3002950

Pure mucinous carcinomas of breast: morphologic features and prognostic correlates.

F Clayton.   

Abstract

Fifty-three pure mucinous carcinomas of breast were studied, with long-term follow-up evaluation (average, 15 years) for 37. The mean age of the patients was 63 years. Long-term survival (Kaplan-Meier method) was 68 per cent, excluding non-tumor-related deaths. Median survival for the patients with fatal carcinomas was 11.3 years. Fatal and disseminated carcinomas were best predicted by the presence of axillary metastases and by tumor cellularity and size. Only five of the patients had axillary metastases at mastectomy, but in four of these five patients distant metastases developed later. The diameters of all ten of the fatal and disseminated carcinomas were at least 2.5 cm, while 17 of the 27 long-term survivors had smaller tumors. All ten of the fatal and disseminated carcinomas had cellularity of more than 10 per cent, while 12 of 27 long-term survivors had less cellular tumors. Tumor cellularity did not correlate with tumor size; these features were entirely independent. Thus, in contrast to the findings of some prior studies with shorter follow-up periods, pure mucinous carcinomas were seen to be slowly growing, but fully malignant, tumors warranting standard breast carcinoma treatment.

Entities:  

Mesh:

Year:  1986        PMID: 3002950     DOI: 10.1016/s0046-8177(86)80152-6

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Pseudomyxoma peritonei from metastatic colloid carcinoma of the breast.

Authors:  D Hawes; R Robinson; R Wira
Journal:  Gastrointest Radiol       Date:  1991

2.  Concerted contractions of tumour fragments derived from a pure mucoid carcinoma of the breast in vitro.

Authors:  J P van Netten; R L Racca; M J Ashwood-Smith; J Armstrong; C Fletcher; N L Goodchild
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Breast Cancers of Special Histologic Subtypes Are Biologically Diverse.

Authors:  Audree B Tadros; Hannah Y Wen; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2018-08-09       Impact factor: 5.344

4.  Personalized medicine in breast cancer: a systematic review.

Authors:  Sang-Hoon Cho; Jongsu Jeon; Seung Il Kim
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

5.  Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

Authors:  Purevsuren Jambal; Melanie M Badtke; J Chuck Harrell; Virginia F Borges; Miriam D Post; Grace E Sollender; Monique A Spillman; Kathryn B Horwitz; Britta M Jacobsen
Journal:  Breast Cancer Res Treat       Date:  2012-12-18       Impact factor: 4.872

6.  Rare breast cancer subtypes: histological, molecular, and clinical peculiarities.

Authors:  Maria Vittoria Dieci; Enrico Orvieto; Massimo Dominici; PierFranco Conte; Valentina Guarneri
Journal:  Oncologist       Date:  2014-06-26

7.  Pure and mixed mucinous breast carcinomas: DNA stemline and prognosis.

Authors:  S Toikkanen; E Eerola; T O Ekfors
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

8.  Mucinous carcinoma of breast: Cytodiagnosis of a case.

Authors:  Sangeeta Sharma; Rani Bansal; Anjali Khare; Nivesh Agrawal
Journal:  J Cytol       Date:  2011-01       Impact factor: 1.000

9.  Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.

Authors:  E Munzone; A Giobbie-Hurder; B A Gusterson; E Mallon; G Viale; B Thürlimann; B Ejlertsen; G MacGrogan; F Bibeau; G Lelkaitis; K N Price; R D Gelber; A S Coates; A Goldhirsch; M Colleoni
Journal:  Ann Oncol       Date:  2015-09-19       Impact factor: 32.976

Review 10.  Exploring the role and diversity of mucins in health and disease with special insight into non-communicable diseases.

Authors:  Santosh Kumar Behera; Ardhendu Bhusan Praharaj; Budheswar Dehury; Sapna Negi
Journal:  Glycoconj J       Date:  2015-08-04       Impact factor: 3.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.